Latest news with #financialStability
Bloomberg
4 days ago
- Business
- Bloomberg
BOE's Breeden Believes UK Labor Market Loosening: Sunday Times
Bank of England's Sarah Breeden believes the UK labor market is loosening, while she sees 'waves of disinflation' continuing, according to an interview the central bank deputy governor for financial stability gave to Sunday Times. Breeden said workers' ability to ask for higher wages and companies' capacity to pay more by increasing prices are both decreasing, the newspaper reported.
Bloomberg
23-05-2025
- Business
- Bloomberg
Some ECB Officials Saw April Rate Cut as Frontloading June Move
April's reduction in borrowing costs was considered by some European Central Bank officials as bringing forward a cut that had earlier been expected to come in June, according to an account of the meeting. 'Recent events had convinced these members that cutting interest rates at the current meeting provided some insurance against negative outcomes and avoided contributing to additional uncertainty in times of financial-market volatility,' the summary showed.
Reuters
21-05-2025
- Business
- Reuters
ECB's Centeno: rate cuts below neutral level may be needed to keep inflation on target
LISBON, May 21 (Reuters) - The European Central Bank may need to cut its key interest rate below the neutral level of 1.5%-2% to prevent inflation from falling below its 2% target in a frail economic setting, ECB policymaker Mario Centeno told a news briefing on Wednesday. "We cannot run the risk of having a monetary policy that puts the inflation rate below the target of 2%," he said after presenting the Bank of Portugal's financial stability report. The ECB interest rate, "in order to be able to keep inflation at the target of 2%, may have to come below the natural rate", he added, estimating the latter to be in the range of 1.5% to 2%. In the face of a more uncertain environment due to the global trade tensions, "we must maintain an increasingly predictable approach and not take steps that create more uncertainty", he said, without specifying if the ECB should cut its rates again at its next meeting in June.
Yahoo
16-05-2025
- Business
- Yahoo
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification
Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. PAVmed Inc (NASDAQ:PAVM) has successfully stabilized its corporate structure and balance sheet, positioning itself as a diversified commercial life science company. The company reported a significant strengthening of its balance sheet with a public offering netting $16.1 million, extending its financial runway well into 2026. Lucid, a subsidiary of PAVmed Inc (NASDAQ:PAVM), is on the cusp of key milestones, including Medicare coverage, and reported revenue of $800,000 with test volumes at the upper end of their target range. PAVmed Inc (NASDAQ:PAVM) has secured financing to restart development of a critical implantable monitor for its subsidiary, Veris, and is close to finalizing a strategic partnership. The company is actively pursuing expansion into the biopharma space, leveraging its infrastructure and track record to explore attractive assets and partnerships. PAVmed Inc (NASDAQ:PAVM) faces uncertainties related to forward-looking statements, which are subject to risks that could cause actual results to differ materially. The company is still awaiting a response from the Medicare program regarding coverage for its e-cigarette diagnostic, which is crucial for accelerating commercialization. There are significant differences in financial reporting due to the deconsolidation of Lucid, which may blur historical understanding of PAVmed Inc (NASDAQ:PAVM)'s financials. The company has a complex corporate structure with multiple subsidiaries, which may pose challenges in management and strategic alignment. PAVmed Inc (NASDAQ:PAVM) is pursuing multiple initiatives simultaneously, including expansion into biopharma, which could stretch its resources and focus. Warning! GuruFocus has detected 8 Warning Signs with PAVM. Q: Now that the pilot program is complete, can you share any feedback from physicians and patients, and has this influenced any changes to the platform before commercialization? A: We've received excellent feedback, meeting all pre-specified performance metrics, including patient satisfaction and clinical success. There is significant enthusiasm, especially with the upcoming implantable monitor. No immediate changes to the platform are needed, but we've learned valuable lessons on implementation processes, which we are applying moving forward. (Respondent: Unidentified_6) Q: Does OSU have exclusive rights to the Veris platform, or are you in talks with other centers? A: OSU has some local rights but nothing that limits our broader commercialization efforts. We aim to use our strong relationship with OSU as a model to replicate at other cancer centers nationwide. (Respondent: Unidentified_6) Q: Can you elaborate on your expansion into the biopharma segment and the financing strategy for this venture? A: Our corporate structure and balance sheet adjustments have positioned us to explore new opportunities, including biopharma. We plan to leverage our infrastructure and track record to pursue attractive assets, particularly those struggling to raise private capital. Financing will follow our model of independently financed subsidiaries, similar to Lucid and Veris. (Respondent: Unidentified_6) Q: Has market volatility affected your ability to raise capital? A: No, we've been fortunate to attract investors aligned with our vision. Our recent financing activities demonstrate our ability to secure necessary funds, and we expect to continue accessing both private and public capital as needed. (Respondent: Unidentified_4) Q: What is the strategic rationale for expanding into biopharma now, given your existing commitments? A: Our structure allows us to pursue shareholder value across various sectors. The biopharma expansion is driven by opportunities identified with our board member, Dr. Sande Agarwal, and aligns with our history of leveraging infrastructure for new ventures. We believe this sector offers streamlined pathways to value creation. (Respondent: Unidentified_6) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
15-05-2025
- Business
- Zawya
Trade tensions, debt, market volatility are key risks for euro zone, ECB says
Trade tensions, financial market volatility and debt sustainability are the three key risks facing the euro zone economy, ECB Vice President Luis de Guindos said on Thursday, previewing the bank's upcoming report on financial stability. "The risks to growth resulting from trade tensions, combined with higher defence spending, may limit the fiscal space available to shield the economy from adverse shocks, address structural challenges associated with climate change, digitalisation and low productivity, and manage the economic implications of ageing populations," de Guindos said. (Reporting by Balazs Koranyi; Editing by Alex Richardson)
